Vertical Transmission of Hepatitis C Virus: Systematic Review and Meta-analysis

Lenka Benova,1,2 Yousra A. Mohamoud,1 Clara Calvert,2 and Laith J. Abu-Raddad1,3,4
1Infectious Disease Epidemiology Group, Weill Cornell Medical College–Qatar, Cornell University, Qatar Foundation–Education City, Doha, Qatar; 2Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, United Kingdom; 3Department of Healthcare Policy and Research, Weill Cornell Medical College, Cornell University, New York, New York; and 4Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington

Background. We conducted a systematic review of estimates of hepatitis C virus (HCV) vertical transmission risk to update current estimates published more than a decade ago.

Methods. PubMed and Embase were searched and 109 articles were included. Pooled estimates of risk were generated for children born to HCV antibody-positive and viremic women, aged ≥18 months, separately by maternal human immunodeficiency virus (HIV) coinfection.

Results. Meta-analysis of the risk of vertical HCV infection to children of HCV antibody-positive and RNA-positive women was 5.8% (95% confidence interval [CI], 4.2%–7.8%) for children of HIV-negative women and 10.8% (95% CI, 7.6%–15.2%) for children of HIV-positive women. The adjusted meta-regression model explained 51% of the between-study variation in the 25 included risk estimates. Maternal HIV coinfection was the most important determinant of vertical transmission risk (adjusted odds ratio, 2.56 [95% CI, 1.50–4.43]). Additional methodological (follow-up rate and definition of infection in children) and risk factors independently predicted HCV infection and need to be captured and reported by future studies of vertical transmission. Studies assessing the contribution of nonvertical exposures in early childhood to HCV prevalence among children at risk of vertical transmission are needed.

Conclusions. More than 1 in every 20 children delivered by HCV chronically infected women are infected, highlighting that vertical transmission likely constitutes the primary transmission route among children. These updated estimates are a basis for decision making in prioritization of research into risk-reducing measures, and inform case management in clinical settings, especially for HIV-positive women in reproductive age.

Keywords. infant; infectious disease transmission; mother-to-child transmission; pregnancy; risk factors.

Hepatitis C virus (HCV) infection is an important global health issue, with as much as 2%–3% of the world’s population affected [1, 2]. Following the implementation of blood and blood product screening, vertical transmission has gained importance as the primary HCV transmission route among children [3]. Assessment of the burden of vertical transmission is essential in countries with high HCV prevalence, such as Egypt [4]. It is also important in countries where HCV is primarily contained in high-risk groups such as people who inject drugs, many of whom are of reproductive age and coinfected with human immunodeficiency virus (HIV) [5].

Vertical transmission encompasses several potential transmission routes from an infected woman to her newborn: intrauterine, intrapartum, and postnatal [6–9]. The risk of HCV vertical transmission has been assessed by several reviews [10–13]. In the most recent systematic review and meta-analysis to provide the pooled risk of vertical HCV infection, Yeung et al showed that...
the risk was 1.7% among children born to all HCV antibody-positive women and 4.3% among children of HCV RNA-positive women [14]. Presence of maternal HCV viremia is a critical factor in mother-to-child transmission of HCV [11], and maternal HIV coinfection is an important risk factor. In children born to HCV-viremic women, the odds of infection was found to be between 1.97 and 2.82 higher among those born to HIV-positive compared with HIV-negative mothers [15, 16]. Mother’s injection drug use, although strongly associated with HIV coinfection, appears to be an independent risk factor for HCV vertical transmission [17] and may be mediated by peripheral blood mononuclear cell infection [18]. There is some evidence that female children may be at higher risk of vertical infection [19]. Other factors, such as mother’s age, parity, HCV genotype, and breastfeeding, do not appear to be associated with the risk [14, 20–24]. Although there is some evidence that prolonged rupture of membranes may increase vertical transmission risk [24], cesarean delivery is not currently recommended as a risk-reducing intervention [25].

The objective of this systematic review is to provide an updated global estimate of the proportion of infants who contract HCV through vertical transmission by identifying all relevant published studies. We produce pooled estimates of vertical transmission risk separately by maternal HIV co-infection and identify potential sources of between-study heterogeneity. The review benefits from more than a decade of new evidence, and is not only important for primary research of potential interventions, but also essential for understanding and communicating the extent of this risk in clinical settings.

**METHODS**

**Conceptual Framework**

To account for the importance of maternal HCV viremia in determining the risk of vertical transmission, we developed a conceptual framework capturing the different types of vertical transmission risk estimates, based on presence of maternal HCV antibody and viremia (Figure 1). This review focused on quantifying the vertical transmission risk to children of HCV antibody–positive and RNA-positive women (pathway C). We also present a narrative summary of included estimates assessing pathway A (children of HCV antibody–positive women irrespective of RNA status) and pathway B (children of HCV antibody–positive but RNA-negative women).

**Data Sources and Search Strategy**

The literature search was conducted on 2 May 2013 using PubMed and Embase databases, combining text and MeSH (Medical Subject Heading) terms (including all subheadings) for vertical transmission of HCV (Supplementary Data 1). No time or language limitations were applied. Two authors (L. B. and Y. A. M.) independently screened titles and abstracts to identify relevant studies. Differences between screeners were reconciled. Reference lists of identified systematic reviews were screened for additional studies. This review is reported according to the Preferred Reporting Items for Systematic

---

**Figure 1.** Conceptual framework for categorizing study estimates of hepatitis C virus (HCV) vertical transmission risk.
Study Selection

Two authors (L. B. and Y. A. M.) independently screened all full-text articles. Studies were included if the full-text version was available or if the abstract provided minimum information for inclusion. Articles had to have analyzed primary data to estimate the risk of vertical transmission (case-control studies were excluded), while specifying the age(s) at which HCV infection status was determined. Only studies using second-generation or later tests for determining HCV antibody presence were included due to the limited sensitivity and specificity of first-generation assays [27, 28]. If no information about the type of antibody test was provided, studies analyzing data collected before the year 1993 were excluded. If neither the HCV antibody test type nor the year of data collection was reported, we included studies published after 2003 to allow for a 10-year interval between the beginning of second-generation test availability and publication of findings.

Risk estimates of vertical transmission (data points) reported by studies were included if they assessed transmission risk among vertically exposed children (from HCV antibody–positive women). We excluded data points in which HIV status among the sample of mothers was mixed (combined groups of HIV-positive and HIV-negative mothers) or unknown (women were not tested for HIV or HIV status was not reported by the study), as well as studies with sample sizes of <11 children assessed for infection at follow-up. Clearance of viremia among children with transient RNA positivity occurs at the median age of 15 months [29, 30], whereas 95% of children diagnosed as uninfected lose maternal antibodies by 12 months of age [31]. In addition to circulating HCV viremia, the presence of HCV antibodies at ≥18 months of age has been used as a surrogate measure of infection [32]. Therefore, only data points that assessed HCV vertical transmission risk in samples of children followed to age ≥18 months were included. If a study presented >1 data point derived from the same sample of children, the data point with the longest follow-up time was used.

Data Extraction

Extraction of information about included data points was conducted using a structured form by 1 author (L. B.) and checked by a second (Y. A. M.) in a random sample of 20% of studies. Two authors (L. B. and Y. A. M.) independently repeated the extraction of all pathway C data points. Extracted information included study type, year(s), and location of data collection, sample recruitment method, number of women included in the study, number of live births, age at assessment of children’s HCV infection status, and definition of HCV infection among children, as well as the number of children followed up and the number considered infected, separately by maternal HIV serostatus. The corresponding author of 1 study describing a pathway C risk estimate was successfully contacted to confirm information.

Analysis

Meta-analysis of the proportion of infants diagnosed with HCV at the age of ≥18 months born to HCV antibody–positive and RNA-positive women (pathway C) was carried out using Stata/SE version 13 and R2.15.3 software, separately by mother’s HIV status. The risk of HCV vertical transmission among children was calculated as the proportion of the number of children diagnosed with HCV divided by the number of children assessed at follow-up. The variance of the raw proportions was stabilized using the Freeman-Tukey–type arcsine square-root transformation [33]. Estimates were pooled using a DerSimonian-Laird random-effects model [34]. Inverse variance weighting was used in pooled analysis. The $I^2$ value was calculated as a measure of heterogeneity, or the proportion of between-study variation in the risk estimate of vertical transmission due to differences between the studies and not chance [35].

A meta-regression was conducted to identify sources of between-study heterogeneity in the risk of vertical HCV transmission. Eight potential sources of heterogeneity were specified a priori. Four of these factors related to vertical transmission or its ascertainment: maternal HIV status (positive/negative), type of women enrolled in the sample (random selection or routine screening during pregnancy or delivery/risk groups such as people who inject drugs and women previously diagnosed with HCV), age of children at ascertainment of HCV status (18–23 months/24–36 months/>36 months), and whether the definition of HCV infection in children included ≥2 positive RNA tests or persistent viremia (yes/no and unclear). The remaining 4 factors related to characteristics of studies: sample size of children at the time of HCV diagnosis (10–49/≥50), study design (prospective/retrospective), median year of study after 2000 (yes/no), and any loss to follow-up of enrolled infants in the study between birth and HCV diagnosis (yes/no). A multivariable meta-regression model was built by adding each variable sequentially, starting with the variable that showed the strongest association with the vertical transmission of HCV in univariate analysis; a variable remained in the multivariable model if it was independently associated with the prevalence of vertical HCV transmission at $P \leq .10$.

RESULTS

The search strategy identified 1792 potentially relevant studies, and 1 additional reference was found by screening reference lists. From the 298 studies screened in full text, 109 studies were included and 331 data points were identified (Figure 2).
Application of inclusion criteria to data points resulted in the exclusion of 261 data points, the majority of which assessed children aged <18 months. We also excluded 4 data points evaluating HCV infection status among vertically unexposed children (born to HCV antibody–negative women); none reported any cases of HCV infection [36–39]. All 3 conceptually defined vertical transmission risk pathways were captured by the 70 data points included in this review.

Among HCV antibody–positive and RNA-positive women (pathway C), 25 data points extracted from 20 studies were included. The age of children at follow-up was between 18 and 23 months in 14 data points, 24–36 months in 9 data points, and 36–72 months in 2 data points. All 25 data points measured maternal HCV antibody and viremia during pregnancy or at delivery. Four studies used RNA presence as the sole marker of infection in children; the remaining 21 studies used both HCV antibody and RNA presence (2 of these required presence of both, 19 the presence of either). Four studies defined HCV infection in children based on 1 RNA-positive test and 19 required ≥2 RNA tests or persistent RNA positivity during follow-up. The estimates of HCV vertical transmission from HIV-negative women ranged from 1.1% to 10.7%, and among HIV-positive women from 4.2% to 28.5%. Meta-analysis of the 17 estimates among children born to HIV-negative women showed that the pooled risk of vertical HCV infection was 5.8% (95% confidence interval [CI], 4.2%–7.8%; Figure 3).

### Table

<table>
<thead>
<tr>
<th>Number of data points</th>
<th>Total</th>
<th>Pathway A</th>
<th>Pathway B</th>
<th>Pathway C</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maternal HIV status</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HIV-negative</td>
<td>46</td>
<td>17</td>
<td>12</td>
<td>17</td>
</tr>
<tr>
<td>HIV-positive</td>
<td>24</td>
<td>13</td>
<td>3</td>
<td>8</td>
</tr>
<tr>
<td>Country income level</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low/middle</td>
<td>3</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>High</td>
<td>67</td>
<td>29</td>
<td>14</td>
<td>24</td>
</tr>
<tr>
<td>Study type</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prospective</td>
<td>62</td>
<td>26</td>
<td>15</td>
<td>21</td>
</tr>
<tr>
<td>Retrospective</td>
<td>8</td>
<td>4</td>
<td>0</td>
<td>4</td>
</tr>
</tbody>
</table>

Pathway A describes vertical transmission from all HCV-antibody positive women. Pathway B from HCV-antibody-positive RNA-negative women and Pathway C from HCV-antibody-positive RNA-positive women. Country income level categories were based on World Bank classification.

**Figure 2.** Study selection for inclusion in the systematic review and meta-analysis. Abbreviations: HCV, hepatitis C virus; HIV, human immunodeficiency virus.
Based on 8 data points, children born to HIV-positive women had a 10.8% (95% CI, 7.6%–15.2%) risk of HCV vertical transmission. There was some evidence of between-study heterogeneity among studies of HIV-negative women ($I^2 = 45.9\%$, $P = .02$), but not among HIV-positive women ($I^2 = 28.8\%$, $P = .20$).

In univariate meta-regression, only mother’s HIV status ($P = .02$) and sample size ($P = .03$) influenced the between-study variation in the risk of vertical HCV transmission (Table 1). In a multivariable model, maternal HIV status ($P = .002$), definition of HCV infection ($P = .03$), age of child at HCV infection determination ($P = .01$), selection of women ($P = .07$), and loss to follow-up ($P = .08$) were independently associated with variation in the risk of vertical transmission, together explaining 51.3% of the between-study heterogeneity. The higher odds of vertical transmission among samples of HIV-positive women compared with HIV-negative women (odds ratio, 2.56 [95% CI, 1.50–4.43]) supported separating the categories in meta-analysis. Additionally, the odds was higher in samples of children aged >36 months compared with children assessed at ages 18–23 months, and marginally lower among samples of mothers identified in screening compared to preidentified or high-risk-group samples. Compared with studies requiring ≥2 positive RNA tests to diagnose HCV infection among children, the odds of vertical infection reported by studies using only 1 RNA positive test was 2.10 times higher (95% CI, 1.08–4.08).

Vertical transmission risk to children of HCV antibody–positive mothers irrespective of HCV viremia (pathway A) was described by 13 data points among HIV-positive mothers (range of estimates, 0.0%–27.3%) and 17 data points among HIV-negative mothers (range of estimates, 4.5%–40.0%). Among the 15 data points describing HCV vertical transmission...
in children born to HCV antibody–positive but RNA-negative women (pathway B), only 1 case of a child diagnosed with vertically acquired HCV infection was identified among the total of 473 children followed up by the studies.

**DISCUSSION**

This systematic review included more than a decade of new evidence to construct pooled estimates of vertical HCV transmission risk; 17 of the 25 included data points were extracted from studies published since the last review in 2001. Our meta-analysis estimated the risk of HCV vertical transmission from HCV antibody–positive and HCV RNA–positive women who are HIV negative at 5.8% (17 estimates; 95% CI, 4.2%–7.8%) and among HIV-positive women at 10.8% (8 estimates; 95% CI, 7.6%–15.2%). The risk to children born to HCV antibody–positive, RNA-negative mothers was negligible; the diagnosis of HCV in 1 child born to a nonviremic woman was potentially related to intermittent maternal viremia or laboratory error. If pregnant women were correctly classified as HCV antibody negative, vertical transmission to their children should not occur in the absence of HCV viremia. The available evidence, although limited to 4 studies, showed this to be the case.

The meta-regression technique allowed us to assess the influence of differences between studies. We found that the risk of HCV vertical transmission among children born to HIV-positive women was more than double compared with those born to HIV-negative women. This finding is similar to previous studies, which suggested that the primary biological mechanism of this association is related to higher HCV viral load among women with HIV coinfection [16, 40].

A large majority of the included pathway C data points used a combination of HCV antibody positivity and RNA positivity for diagnosis of HCV among children. However, limited HCV antibody clearance may occur after the age of 18 months and in the absence of viremia may reflect late clearance of maternal

### Table 1. Meta-regression Model

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>No. of Data Sets</th>
<th>Univariable Analysis</th>
<th>Multivariable* Analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mother’s HIV status</td>
<td></td>
<td>OR (95% CI)</td>
<td>P Value</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HIV negative</td>
<td>17</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>HIV positive</td>
<td>8</td>
<td>2.12 (1.14–3.94)</td>
<td>.02</td>
</tr>
<tr>
<td>Definition of infection in children includes ≥2 positive RNA tests</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>21</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>4</td>
<td>1.61 (0.68–3.84)</td>
<td>.26</td>
</tr>
<tr>
<td>Selection of mothers</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Routine screening</td>
<td>14</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Preidentified/risk factors</td>
<td>11</td>
<td>1.21 (0.63–2.33)</td>
<td>.55</td>
</tr>
<tr>
<td>Age of child at determination of HCV status</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18–23 mo</td>
<td>14</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>24–36 mo</td>
<td>9</td>
<td>0.85 (0.44–1.64)</td>
<td>.15</td>
</tr>
<tr>
<td>&gt;36 mo</td>
<td>2</td>
<td>2.76 (0.87–8.80)</td>
<td>.15</td>
</tr>
<tr>
<td>Sample size of children assessed at follow-up</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11–49</td>
<td>12</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>≥50</td>
<td>13</td>
<td>0.52 (0.29–0.93)</td>
<td>.03</td>
</tr>
<tr>
<td>Study design</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prospective</td>
<td>21</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Retrospective</td>
<td>4</td>
<td>1.24 (0.51–3.02)</td>
<td>.61</td>
</tr>
<tr>
<td>Median year of study after 2000</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>20</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>5</td>
<td>1.35 (0.54–3.39)</td>
<td>.50</td>
</tr>
<tr>
<td>Loss to follow-up between birth and HCV status determination</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>21</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>4</td>
<td>1.56 (0.66–3.73)</td>
<td>.30</td>
</tr>
</tbody>
</table>

**Abbreviations:** CI, confidence interval; HCV, hepatitis C virus; HIV, human immunodeficiency virus; OR, odds ratio.

* Total between-study variation explained by final multivariable model: 51.3%.
antibodies or cleared infection [32]. The risk of vertical HCV infection derived from samples of older children was expected to be lower compared with younger children, in the absence of nonvertical HCV transmission. Our analysis showed that risk estimates of vertical HCV infection increased with higher age at HCV status determination, although this result was largely based on 2 estimates published by the same study.

A previous systematic review found that HCV vertical transmission risk to children born to HCV antibody-positive women was higher in studies requiring a minimum of 2 positive HCV RNA results than in studies with \geq 1 positive RNA test (7.1% and 3.9%, respectively), a result the authors attributed to variable study methods [14]. Although their pooled risk estimates cannot be directly compared with our analysis of a subset of children born to HCV antibody-positive and RNA-positive women, our results showed that the risk of HCV infection in children was lower when the more rigorous definition was applied, as would be expected when applying more stringent criteria.

Half of the between-study variation of all estimates in HCV antibody-positive, RNA-positive women was explained by the adjusted meta-regression model. Additional methodological and/or biological sources of heterogeneity may therefore exist. The type of women enrolled into studies carried a marginal independent effect on the risk of vertical transmission. The categories capturing women’s selection (routinely screened vs pre-identified based on risk factors) may have acted as proxies for more specific mechanisms of association, such as history of injection drug use. Although these other mechanisms could explain the effect observed, their assessment was not possible due to inconsistent reporting by studies. The marginally higher risk among studies reporting any loss to follow-up of children may be explained by higher likelihood of remaining in observation for children with early HCV RNA positivity, who are also more likely to be diagnosed with infection. Potential selection bias may have originated from low enrollment rates in studies, but this factor was not consistently reported in studies and therefore not included in the meta-regression.

We identified potential sources of heterogeneity prior to conducting meta-regression to reduce the likelihood of identifying spurious associations. However, the results of the meta-regression should be interpreted with caution. Only 25 data points capturing risk of vertical transmission from HCV antibody-positive and RNA-positive women were included in the meta-regression, resulting in small numbers of studies in some categories. The meta-regression results may be subject to residual confounding, and the associations identified on the level of studies may not operate in the same direction or magnitude on the individual level. Another limitation of this study includes a search strategy focused on 2 databases of published literature, and it is possible that unpublished studies of HCV vertical transmission were not identified. We excluded 13 studies from non-English-language journals on the basis of unavailability of full text. During full-text screening, we may have excluded some valid estimates because the HCV antibody test generation was not specified. However, the number of such studies was small, and their absence was unlikely to have significantly biased the results.

The body of evidence assessing risk factors of HCV vertical transmission, including this systematic review, is based solely on observational studies. No interventions during pregnancy or at the time of delivery have been demonstrated to reduce the risk [24]. The current treatment regimen of pegylated interferon and ribavirin is contraindicated during pregnancy [13], and new treatments have not yet been evaluated for use in pregnant women [41, 42]. The proportion of data points from low- and middle-income countries was considerably lower among included data points (4% [3/70]) compared with all identified data points (18% [60/331]). More rigorous primary research from different contexts is needed to identify remaining sources of heterogeneity, such as delay in HIV diagnosis and treatment.

This systematic review provided updated pooled estimates of HCV vertical transmission risk. We developed a conceptual framework to identify transmission pathways based on maternal HCV antibody and viremia. In line with previous evidence, we showed that vertical transmission risk appeared to be limited to infants of viremic mothers, where it ranged from 5.8% to 10.8% depending on maternal HIV coinfection. This study highlighted the importance of using a standard definition of HCV infection in vertically exposed children. Additional risk factors warrant further examination in primary research, namely, maternal HIV treatment and HCV genotype. Such research would contribute to quantifying the contribution of HCV vertical transmission to HCV incidence in high-burden countries and in high-risk populations globally. In summary, >1 in every 20 children delivered by women chronically infected by HCV are vertically infected. These updated estimates can serve as a basis for decision making in research into risk-reducing measures, as well as inform clinical case management.

Supplementary Data

Supplementary materials are available at Clinical Infectious Diseases online (http://cid.oxfordjournals.org). Supplementary materials consist of data provided by the author that are published to benefit the reader. The posted materials are not copyrighted. The contents of all supplementary data are the sole responsibility of the authors. Questions or messages regarding errors should be addressed to the author.

Notes

Acknowledgments. The authors thank Dr Ashwini Deshmukh and Suzanne Rimeo for their assistance with locating full-text articles; Dr Ryosuke Omori, Susanne Awad, Dr Matej Beňo, and Dr Jingxuan Shan for assistance with translating manuscripts from foreign languages; Dr Sara L. Thomas for invaluable advice on an earlier draft of the manuscript;
Timothy Collier for assistance with statistical analysis; and the Biostatistics, Epidemiology, and Biomathematics Research Core at the Weill Cornell Medical College in Qatar.

Author contributions. L. B. and L. J. A.-R. conceptualized the study; L. B. and Y. A. M. conducted the literature search, screened references, and extracted data; and L. B., Y. A. M., and C. C. conducted data analysis and wrote the first draft of the article. All authors contributed to the interpretation of findings and drafting of the manuscript.

Disclaimer. The statements made herein are solely the responsibility of the authors. No funding bodies had any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Financial support. This work was supported by the Qatar National Research Fund (a member of Qatar Foundation; NPRP 04-924-3-251).

Potential conflicts of interest. All authors: No reported conflicts.

All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

mother-to-infant transmission of hepatitis viruses B, C, and E in south-
HIV in T-cell activation and exhaustion in HIV/HCV coinfection. PLoS
One 2013; 8:e59302.
41. Lavitz E, Poordad FF, Pang PS, et al. Sofosbuvir and ledipasvir fixed-dose
combination with and without ribavirin in treatment-naive and previously
treated patients with genotype 1 hepatitis C virus infection (LONESTAR):
42. Asselah T. Sofosbuvir for the treatment of hepatitis C virus. Expert Opin